KDC-MN-381 – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Methamphetamine is the N-methylated cousin of amphetamine. The extra methyl group makes it more lipophilic and substantially better at crossing into the brain, so d-methamphetamine releases central dopamine roughly five times more potently than d-amphetamine on a per-milligram basis. It actually has FDA approval as Desoxyn (1944) for ADHD and obesity, though prescriptions are vanishingly rare; the public knows it primarily as the illicit Schedule II drug. Same mechanism as amphetamine: reverses the monoamine transporters to force release rather than blocking reuptake. The l-enantiomer is the active component of Vicks Vapor Inhaler, which is a strange historical footnote. Used in research as a high-potency reference monoamine releaser. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

38/100

Textbook monoamine releaser with real reference value but settled science and Schedule II friction throughout

Look, methamphetamine occupies a genuinely strange position in a research library. It’s Schedule II, massively studied, FDA-approved since 1944, and its pharmacology is about as well-characterized as any small molecule in existence. That combination of thorough understanding and intense regulatory burden makes it a difficult call for most programs.

The mechanism isn’t interesting from a discovery standpoint. Reverse transport at DAT, NET, and SERT with preferential dopamine release is chapter one of stimulant pharmacology. The N-methyl group relative to amphetamine confers greater CNS penetration and a roughly 5-fold potency advantage at central dopamine release, but the N-methylation story was settled decades ago. There’s no unexplored receptor interaction here, no second target that opens up new biology, no emerging indication that changes the calculus. We’ve read every chapter of this book.

Where methamphetamine retains genuine bench value is as a reference standard. If your program involves characterizing novel DAT substrates or inhibitors, running abuse-liability profiling on candidate stimulants, or building monoaminergic neurotoxicity models, meth is the positive control you benchmark against. The striatal dopaminergic neurotoxicity it produces in rodents is a real and reproducible research model, used extensively by the Ricaurte lab and others to probe the limits of monoaminergic resilience and recovery. That role doesn’t go away just because the compound is old.

But here’s the thing: d-amphetamine sulfate does most of the same jobs. For a research program that needs a monoamine releaser reference, amphetamine serves nearly all the same functions with a slightly cleaner regulatory profile (still Schedule II, but more familiar to institutional DEA coordinators). Meths advantages, specifically the enhanced CNS penetration and longer 9-12 hour half-life, matter in specific experimental designs but don’t build a compelling case for general library inclusion.

The evidence quality is excellent in the sense that everything about this compound is known. That’s actually the scoring problem. You can’t rate high on novelty, mechanism promise, or differentiation when the science is essentially finished. The translational signal is clear and thoroughly replicated, but there’s nothing new being translated. Where researchers are doing interesting work adjacent to this compound, they’re typically using it as a tool, not studying it as a discovery target.

What we’d say to bench scientists: procure it if your specific research program requires a high-potency monoamine release reference or an addiction neurobiology stimulus with decades of precedent literature. Don’t add it speculatively. The DEA Schedule II overhead, storage requirements, and institutional scrutiny are real costs, and they aren’t worth paying unless the experimental question specifically demands this compound rather than a functional analog with fewer compliance hurdles.

Novelty: 10
Mechanism promise: 18
In-category differentiation: 32
Evidence quality: 78
Translational signal: 60
Research bench value: 50

Rationale Methamphetamine scores low on novelty and mechanism because its pharmacology is essentially finished knowledge, but retains meaningful bench utility as a DAT/NET reference standard and addiction neuroscience model compound. The Schedule II cap of 65 does not bind because the weighted score lands at 38 on its own merits.

N-methylated phenethylamine stimulant

The N-methylated analog of amphetamine; FDA-approved (Desoxyn) for ADHD and obesity but principally encountered as an illicit drug; a research-grade pharmacology probe.

Abstract

Methamphetamine (N-methyl-1-phenylpropan-2-amine; CAS 537-46-2; molecular formula C10H15N; molecular weight 149.23) is the N-methylated analog of amphetamine, approved by the FDA in 1944 (Desoxyn) for narcolepsy, ADHD, and obesity. Mechanism is the same as amphetamine (monoamine release via reverse transport) with greater CNS penetration owing to the increased lipophilicity from N-methylation. The d-enantiomer (d-methamphetamine) is approximately 5-fold more potent than d-amphetamine at central dopamine release; the l-enantiomer (l-methamphetamine) is the active component of Vicks Vapor Inhaler. Plasma half-life is approximately 9 to 12 hours. Schedule II prescription drug; principally encountered as illicit Schedule II. Used as a research-grade reference compound for monoamine release pharmacology and as a clinical (rare) ADHD medication.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-381Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-381

Methamphetamine (Research)

Abstract

Read the full monograph